HSR25-195: Risk of Venous and Arterial Thrombosis As Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis

Zin Myint; Kris Varothai; Megan Foley; Donglin Yan

doi:10.6004/jnccn.2024.7237

HSR25-195: Risk of Venous and Arterial Thrombosis As Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis

Zin Myint, Kris Varothai, Megan Foley, Donglin Yan

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	23
Issue number	35
DOIs	https://doi.org/10.6004/jnccn.2024.7237
State	Published - Mar 28 2025

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2024.7237

Cite this

@article{ba7732e5b04d40dfacee198a3f0afeb3,

title = "HSR25-195: Risk of Venous and Arterial Thrombosis As Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis",

author = "Zin Myint and Kris Varothai and Megan Foley and Donglin Yan",

year = "2025",

month = mar,

day = "28",

doi = "10.6004/jnccn.2024.7237",

language = "English",

volume = "23",

number = "35",

}

HSR25-195: Risk of Venous and Arterial Thrombosis As Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis. / Myint, Zin; Varothai, Kris; Foley, Megan et al.
In: Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 23, No. 35, 28.03.2025.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - HSR25-195

T2 - Risk of Venous and Arterial Thrombosis As Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis

AU - Myint, Zin

AU - Varothai, Kris

AU - Foley, Megan

AU - Yan, Donglin

PY - 2025/3/28

Y1 - 2025/3/28

UR - http://www.scopus.com/inward/record.url?scp=105002486511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=105002486511&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2024.7237

DO - 10.6004/jnccn.2024.7237

M3 - Article

C2 - 40154334

AN - SCOPUS:105002486511

SN - 1540-1405

VL - 23

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 35

ER -

HSR25-195: Risk of Venous and Arterial Thrombosis As Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this